Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Sarcoma 3Breast 3Thoracic 2Other solid neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1

Conditions

Solid Tumor 1Locally Advanced or Metastatic Solid Tumors 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
efineptakin alfa × Other solid neoplasm × Clear all
NCT03733587 2020-05-14

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Genexine, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumor

NCT03478995 2020-05-11

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Genexine, Inc.

Phase 1 Completed
35 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡